Cite
HARVARD Citation
Gan, H. et al. (2018). Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-oncology. 20 (6), pp. 838-847. [Online].